The latest price target for Bio-Techne (NASDAQ:TECH) was reported by Scotiabank on October 31, 2024. The analyst firm set a price target for $88.00 expecting TECH to rise to within 12 months (a possible 23.06% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Bio-Techne (NASDAQ:TECH) was provided by Scotiabank, and Bio-Techne maintained their sector outperform rating.

The last upgrade for Bio-Techne Corp happened on January 10, 2023 when Wells Fargo raised their price target to $90. Wells Fargo previously had an underweight for Bio-Techne Corp.

The last downgrade for Bio-Techne Corp happened on May 22, 2024 when Citigroup changed their price target from N/A to $85 for Bio-Techne Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Techne, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Techne was filed on October 31, 2024 so you should expect the next rating to be made available sometime around October 31, 2025.

While ratings are subjective and will change, the latest Bio-Techne (TECH) rating was a maintained with a price target of $83.00 to $88.00. The current price Bio-Techne (TECH) is trading at is $71.51, which is out of the analyst’s predicted range.